A remarkable increase in total homocysteine concentrations in the CSF of migraine patients with aura

Headache

Volumn 50, Issue 10, 2010, Pages 1561-1569

  Isobe, Chiaki ^a,b   Terayama, Yasuo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b Chitose Daiichi Hospital   (Japan)

Author keywords

cardiocerebrovascular conditions; cerebrospinal fluid; free homocysteine; migraine with aura; migraine without aura; total homocysteine

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; ATHEROGENESIS; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BRAIN CHEMISTRY; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; YOUNG ADULT;

EID: 78649283268     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01713.x     Document Type: Article

References (48)

1. Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovin G,. Prevalence of migraine and non-migrainous headache-head-HUNT, a large population-based study. Cephalalgia. 2000; 20: 900-906.
2. Goadsby PJ,. The vascular theory of migraine - A great story wrecked by the facts. Brain. 2009; 132: 6-7.
3. Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR,. Migraine and the risk of stroke, TIA, or death in the UK (CME). Headache. 2007; 47: 1374-1384.
4. Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med. 2007; 167: 795-801.
5. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE,. Migraine and risk of cardiovascular disease in women. JAMA. 2006; 296: 283-291.
6. Liew G, Wang JJ, Mitchell P,. Migraine and coronary heart disease mortality: A prospective cohort study. Cephalalgia. 2007; 27: 368-371.
7. Hering-Hanit R, Gadoth N, Yavetz A, Gavendo S, Sela B,. Is blood homocysteine elevated in migraine? Headache. 2001; 41: 779-781.
8. Kurth T, Ridker P, Buring J,. Migraine and biomarkers of cardiovascular disease. Cephalalgia. 2008; 28: 49-56.
9. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG,. A quantitative assessement of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274: 1049-1057.
10. Datta S, Pal SK, Mazumdar H, Bhandari B, Bhattacherjee S, Pandit S,. Homocysteine and cerebrovascular accidents. J Indian Med Assoc. 2009; 107: 345-346.
11. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG,. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995; 346: 1395-1398.
12. Wright CB, Paik MC, Brown TR, Stabler SP, Allen RH, et al. Total homocysteine is associated with white matter hyperintensity volume: The Northerm Manhattan Study. Stroke. 2005; 36: 1207-1211.
13. Censori B, Partziguian T, Manara O, Poloni M,. Plasma homocysteine and severe white matter disease. Neurol Sci. 2007; 28: 259-263.
14. Mei W, Rong Y, Jinming L, Youngjun L, Hui Z,. Effect of homocysteine interventions on the risk of cardiocerebrovascular events: A meta-analysis of randomized controlled trials. Int J Clin Pract. 2010; 64: 208-215.
15. Parnetti L, Bottigliert T, Lowenthal D,. Role of homocysteine in age-related vascular and non-vascular disease. Aging Clin Exp Res. 1997; 9: 241-257.
16. Hus AH,. Homocysteine species as components of plasma redox thiol status. Chin. Chem. 1995; 41: 340-342.
17. Rozen R,. Genetic predisposition of hyperhomocysteinemia: Deficiency of methylenetetrahydrofolate reductase (MTHFR). Throm. Haemost. 1997; 78: 523-526.
18. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolatereductase. Nat Genet. 1995; 10: 111-113.
19. Scher AI, Terwindt GM, Verschuren WM, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol. 2006; 60: 621-622.
20. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari MD, Launer LJ,. Cardiovascular risk factors and migraine: The GEM population-based study. Neurology. 2005; 64: 614-620.
21. Headache Classification Committee of the International Headache Society. The Intenational Classification of Headache Disorders (second edition). Cephalalgia. 2004; 24 (Suppl. 1): 1-160.
22. Saremi F, Channual S, Raney A, et al. Imaging of patent foramen ovale with 64-section multidetector CT. Radiology. 2008; 249: 483-492.
23. Kara I, Sazci A, Ergul E, Kaya G, Kilic G,. Association of C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Mol Brain Res. 2003; 111: 84-90.
24. Kowa H, Fusayasu E, Ijiri T, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett. 2005; 374: 129-131.
25. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Liberman JN,. Validity of the Migraine Disability Assessment (MIDAS) score in comparison with a diary-based measure in a population sample of migraine sufferers. Pain. 2000; 88: 41-52.
26. Moschiano F, D'Amico D, Usai S, et al. Homocysteine plasma levels in patients with migraine with aura. Neurol Sci. 2008; 29: 173-175.
27. Hering-Hanit R, Gadoth N, Yavetz A, Gavendo S, Sela B,. Is blood homocysteine elevated in migraine? Headache. 2001; 41: 779-781.
28. Kurth T, Ridker PM, Buring JE,. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia. 2008; 28: 49-56.
29. Ulvik A, Vollset SE, Hoff G, Ueland PM,. Coffee consumption and circulation B-vitamins in healthy middle-aged men and women. Clin Chem. 2008; 54: 1489-1496.
30. Vinukonda G, Shaik Mohammad N, Md Nurul Jain J, Prasad Chintakindi K, Rama Devi Akella R,. Genetic and environmental influences on total plasma homocysteine and coronary artery disease (CAD) risk among South Indians. Clin Chem Acta. 2009; 405: 127-131.
31. Kowa H, Yaui K, Takeshima T, Urakami K, Sakai F, Nakashima K,. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a risk factor for migraine. Am J Med Genet. 2000; 96: 762-764.
32. Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR,. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med. 2004; 2: 3.
33. Toclt U, Freudenberg J, Goebel I, et al. MTHFR C677T polymorphism and migraine with aura. Ann Neurol. 2006; 60: 621-622.
34. Oterino A, Toriello M, Valle N, et al. The relationship between homocysteine and genes of folate-related enzymes in migraine patients. Headache. 2009; 8: 26-49.
35. Kaunisto M, Kallela M, Hamalainen E, et al. Testing of variants of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine with aura. Cephalalgia. 2006; 26: 1462-1472.
36. Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L,. Association of the C677T polymorphism in the MTHFR gene with migraine: A meta-analysis. Cephalalgia. 2009; 29: 818-825.
37. Di Fabio R, Glugni E, Angeloni I, et al. Contrast echocardiography and migraine in divers with patent foramen ovale. Can J Neurol Sci. 2009; 36: 740-744.
38. Moaref AR, Petramfar P, Aghasadeghi K, et al. Patent foramen ovale in patients with tension headache: Is it as common as in migraineurs? An age- and sex-matched comparative study. J Headache Pain. 2009; 10: 431-434.
39. Tatlidede AD, Oflazoǧlu B, Celik SE, Anadol U, Forta H,. Prevalence of patent foramen ovale in patients with migraine. Agri. 2007; 19: 39-42.
40. Carod-Artal FJ, Da Silveira Ribeiro L, Braga H, Kummer W, Mesquita HM, Vargas AP,. Prevalence of patent foramen ovale in migraine patients with and without aura compared with stroke patients. A transcranial Doppler study. Cephalalgia. 2006; 26: 934-939.
41. Selley ML, Close DR, Stern SE,. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging. 2002; 23: 383-388.
42. Isobe C, Murata T, Sato C, Terayama Y,. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci. 2005; 77: 1836-1843.
43. Isobe C, Abe T, Terayama Y,. Homocysteine may contribute to pathogenesis of RNA damage in brains with Alzheimer's disease. Neurodegener Dis. 2009; 6: 252-257.
44. Isobe C, Abe T, Terayama Y,. L-DOPA therapy increased homocysteine concentration in the cerebrospinal fluid from patients with Parkinson's disease. J Clin Neurosci. 2010; 17: 717-721.
45. Ratan RR, Murphy TH, Baraban JM,. Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem. 1994; 62: 376-379.
46. Ratan RR, Murphy TH, Baraban J,. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J Neurosci. 1994; 14: 4385-4392.
47. Tietjen GE,. Migraine as a systemic vasculopathy. Cephalalgia. 2009; 29: 987-996.
48. Storer RJ, Goadsby PJ,. Microiontophoretic application of serotonin (5HT) 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain. 1997; 120: 2171-2177.